Bank of Montreal
ACAD icon

Bank of Montreal’s Acadia Pharmaceuticals ACAD Stock Holding History

Bank of Montreal’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,000
Closed -$254K – 4031
2016
Q3 		$254K Buy
+8,000
New +$271K ﹤0.01% 2350

Other funds holding ACAD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Bank of Montreal's ACAD Position: Q2 2026 in Review

Bank of Montreal reduced its Acadia Pharmaceuticals (ACAD) stake by 32% in Q2 2026, selling an estimated $169K and leaving 16,509 shares worth $418K. The position accounts for ﹤0.01% of the portfolio, ranked #2567.

Bank of Montreal first reported a position in ACAD in Q1 2014 and has held it in 38 quarters since. The position peaked at $4.5M in Q4 2022. 248 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Bank of Montreal held 16,509 shares of Acadia Pharmaceuticals worth $418K as of Q2 2026.
  • Bank of Montreal sold 7,684 Acadia Pharmaceuticals shares in Q2 2026, an estimated $169K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2567 holding.
  • Bank of Montreal first reported a position in Acadia Pharmaceuticals in Q1 2014 and has held it in 38 quarters since.
  • Bank of Montreal's Acadia Pharmaceuticals position peaked at $4.5M in Q4 2022.
  • 248 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.